<SEC-DOCUMENT>0001193125-23-048812.txt : 20230224
<SEC-HEADER>0001193125-23-048812.hdr.sgml : 20230224
<ACCEPTANCE-DATETIME>20230224163030
ACCESSION NUMBER:		0001193125-23-048812
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230224
FILED AS OF DATE:		20230224
DATE AS OF CHANGE:		20230224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		23667889

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d444919d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of February, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;24, 2023, Kazia Therapeutics Limited (the &#147;Company&#148;) issued an ASX release titled &#147;Results of
EGM&#148; in connection with its Extraordinary General Meeting that was held on February&nbsp;24, 2023 at 3:00 p.m. (Sydney time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company hereby incorporates by reference the information contained herein into the Company&#146;s registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT>
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d444919dex991.htm">ASX Release of Kazia Therapeutics Limited dated February&nbsp;24, 2023 (Extraordinary General Meeting Results) </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> (Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;24, 2023</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d444919dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g444919dsp3a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX ANNOUNCEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24&nbsp;February 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESULTS OF EGM
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 24&nbsp;February 2023</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is
pleased to announce the results of the EGM held today at 3pm in the Company&#146;s offices. All resolutions were carried, and the results are attached. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM
AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Extraordinary General Meeting </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Friday, 24&nbsp;February 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Results of Meeting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Resolution details</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Instructions given to validly appointed proxies</B><br><B>(as at proxy close)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of votes cast on the poll<BR>(where&nbsp;applicable)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Resolution<BR>Result</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Resolution</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Resolution<BR>Type</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proxy&#146;s<BR>Discretion</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Abstain</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Abstain*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carried /<BR>Not&nbsp;Carried</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">1. Ratification of Prior Issue of Atm Shares under Listing Rule 7.1A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">40,046,080<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81.66%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">8,761,171<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17.86%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">236,149<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.48%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">143,981</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">40,987,091<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82.39%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">8,761,171<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17.61%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">143,981</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">2. Ratification of Prior Issue of Tranche 1 Placement Shares under listing rule 7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">18,447,640<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73.14%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">6,537,485<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25.92%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">236,149<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.94%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">23,966,107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">19,388,651<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74.78%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">6,537,485<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25.22%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">23,966,107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">3. Ratification of Prior Issue of Tranche 1 Placement Shares under listing rule 7.1A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">18,372,387<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72.84%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">6,582,128<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26.10%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">266,149<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1.06%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">23,966,717</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">19,343,398<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74.61%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">6,582,128<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25.39%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">23,966,717</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">4. Approval to Issue Tranche 2 Placement Shares under listing rule 7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">18,256,856<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72.52%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">6,681,148<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26.54%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">236,149<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.94%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">24,013,228</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">19,197,867<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74.18%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">6,681,148<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25.82%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">24,013,228</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.
</P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g444919dsp3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g444919dsp3a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MC*'0'&Y"0 RY!&1D<5Y#35M&K[?\ ^I4HNZC)-Q=FDUH^SML_(90,* "@ H
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M>5I1]QQ:YVKK52C?EYKZ["I4:$Z%6JZ;3PSE=-R]Y-/D3L]'&5N:UM%J>5_
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M4H\G,DG%64?=O9V2WU(J8BK5A"%1\WLVVI._-KNKWVT/)JW, H * "@ H *
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M>_O)<NP&(K2VGD(SDB,A020"VU'RV7WNR_$$F]$MKO[E=_<D5J8CTK5?@_\
M$G0]+L-9U/PG?6FEZI=VUCIMX9["2*]O+N6&&WM[807;M+*TMQ I"J=IF3?M
MW"L8UZ,FXQFFXJ[6NB7R\C:5"K!)N#BF[+;?IU//KVSNM.O+O3[Z"2UO;"YG
ML[RVE&V6WNK65X+B"11TDCE1T(]5-:III-;/5>G0R:<6TU9QT:]"M3$% !0
M4MO*P%U].O8].@U5X&73[F\NM/@N2R;7O+&&TN+J (&WAHX;^T8DJ%/G  D@
M@)-7Y;ZQ2=O)W2_)CY6DG;2[2?FK7^ZZ*54(NKIM\VG2ZNMK*=,M[VWTV:\
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M%V;MI&R;[7O;\F9U4(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M#A<NJ5:LY8N$HQU>]G*3?EVUO\CW,3CZ=&G".%E&4E966JC%+M]R7S/C>/\
MX*(_M)(Z,^J>$I$5U9HCX5LU#JI!9"R2AE# $94@C/'-=_\ 96$[27_;S.#^
MU,4OY-/[O_!/NWXQ_'G]F?X^_ 75O#FL?$7PYHFO:WX:M==TG3M12_;4/#7C
M*TLUU"PM93'8.5EAU 26$[0$^9!<7*H66;GS</AL9A,3&4:,I1A+E;5K.%[/
MKVU5]G;L>E6Q&$Q&&<'5C%RC=)[QDE==.CT?E<_"JOI3YP_:/]C3XG_LU?!;
MX/:;;:M\3?#%AXW\53/KWC(745]%?6MT6>WTW1)&^P%OL^GV*J H=XS/=7DT
M9VW'/SV/HXO$8A\M&3IT_=A:UK=7OU?X670]_ 5<+AZ$4ZT8U):ROH[]%_VZ
MOQN^I[MKGQG_ &&_$VI3ZSXDUCX->(-7N5B6XU76_"EAJNHSK!$D$"S7U]H,
MLTJQPQI&@9SM5%48  KFCA\QII1A&K"*V49-+[DTCIE7P$G>4J4GW:3?WM'X
M_?M;ZM\,-9^-6LWWPA'AM?!;:/X?CM?^$3TR'2-%-]%IL2Z@8+.WM+:,2^?Q
M(ZQ?,P.22#7O8"-:.'BJ_-[1.7Q.[M?35MGAXYT77;H<J@E'X597Z[6/F>NP
MXS]EOVC/V@O@SXL_9)N_ _ASX@:)JWBR?P[\/+2+0K87OVXW&EZIX;N-0B*R
MVB*C00V=RS[F&/)(ZX!^?PF%Q%/'*I*DXP4IN^EK-22Z^9[^+Q-">"E3A5C*
M;C"T5OHXWT\K'XTU] > ?K%^P9\1?@#\'_A_XCUWQMX^\/:%X\\4ZS+%=6MZ
MEZU_8>&]&C1-,M$$-C(<3WDNH73")V$@>U##?  /#S.EBJ]6$*=*4J5-:-6M
MS/=[]%9??W/:RVIAJ%*4JE6,:DGJGNHK9?F_N['DOB__ (**_'";Q5XBE\'7
MOAVR\)MK6I?\(W:WWAJUN;V'0UNY5TL7D\KAI+LV8A:0D#YV8   "MZ>4X90
MA[12<TES6EI>VMEVN8SS2OSR]GRJ";Y;QUM?2^N]CZ4_9A_;SLO$Z>*]'_:'
M\2>'=!N81:7GAS5QI<FGZ=?V<JO;:GI-S%9Q31BXB<6\T9< RI<SJ>( #QXS
M+'3Y)82$I+:2O=I]'K;T\K+N=6$S%3YXXF48-6Y7:RMLUUV_K8_+CXW:3X'T
M;XJ>,[3X;:Y8>(? TFK/J'AN_P!-$RVL.GZG''J"Z6@GBC;_ (ETMS)8[MI#
M"S#9^8X]K#2J.A3]K%QJ)6DGO=:7^=K_ #/(Q$:<*U14I*5.]XM;6>MOEM\C
MRJMS * "@ H * "@ H * "@"]INEZGK%Y'IVCZ=?:IJ$R3R0V.FVEQ?7DL=K
M;RW5R\=M:QO(Z0VL$TSE5(2.%W;"H2)<HP5Y-12ZMV79;_<.,7)VBG)]$E=Z
M>2[&KI?@[Q=K>EWVMZ+X6\1ZOHNEF4:EJ^EZ'J=_I>G&W@6ZG%]?VEK)!:&.
MV99G$LB;8V#G"D&DZE.#493C&3V3:3[:)ZE1IU))RC"4HQW:3:5M=6E9611E
MT+6[>*PGFT;58(-4L+O5-+FET^[CBU'3+ W2WVHV$CPA;RPMC8WHEN(2\<?V
M.?>R^4^U\T=5S+W6DU=:-VLGV;NK+S0N62M[K2:;6CV6[7DK.[Z6*T6GW\UM
M)>PV-Y+9PSQ6LMW%;3/;17,^?(MY)T0HD\F#LC+!FQP#3ND[72?1>GEY"47:
MZ3LM+VT+NI^'?$&BRVT&L:%K&DS7>X6<.IZ9>V$MUL9$;[-'=0(TVUI(U.P-
M@NHZD4HSA*_+)24=[-.WW;#<)1LG%QOLFFB)M#UJ.>^M7T?5$N=+A-SJ5NVG
MW:SZ=;KLW3WT1A#6D(WIEY0BC>O/(HYHV7O*ST6J_ .62NN5IQW5GIZ]BK)9
M7D%M;7DMI<PV=V95M+J2"6.VNFMV"3BVG9 DQC<A7",VTG!P:=U=JZO'==NV
MG05FDG9I/9]-.WH;6DV?BV*=]/T.R\0+<^(-(EA:RTVTU W&LZ'+(D\RBWMH
MR]]IC2V22,0KQDVH)_U?$R=.UY.-H/=M:/\ 1ZE14UI%27,MDGJO3JM#.N-%
MUBSCNY;K2=3M8K"[^P7TMQ874$=E?8)%E=O)$HMKO /[F0J_'W::E'1*2U5T
MKK;NO(3C)7]UI1=GH]'V\F6W\*^)XK?3KN3PYKT=IJ\UI;Z3<OH^H);ZG<7Z
M&2P@TZ9K<)>S7,8+0I"7:11E PI<\+M<\;QO=76EM[]K=>P<DTE[K2E:VCU[
M6[^5BI=:)K-C>3Z=>Z1J=GJ%K ]U<6%U875O>6]K' ;J2YGM98EDA@6U!F,C
M*%$8WD[>::E%I-236R::MV_X .,HNSBXM=+-.WH9E42% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!T_@O6+7P[XL
M\/:W?1/-9Z7JMI=W*1JKR>3%*"[Q(Q :1%RZC(R4 R.HZL#6AA<9AJ]1-PHU
M(RDEO9/6R?5;KS1YF<X.KC\JS# T)*%;$T*E.#;:7,XV2;6J3>C=G9-Z/8^D
M_BKXPT;XL6_A[P7X!$NO:Q/JHU(RFUFL(;."VL+Q)8I)M1C@V96?S'(^0"WP
M6+%5/T^;XZAG$<-@<N3KUI5.>_*X**C"2:O-1MO=O9*.]['YQPKD^,X4J9AG
M&?.. P=.A[%1YXU7.4ZM-QDHT7.]G'EBG[S<]DKL^?\ Q#X<\9_#:]_L_4C=
MZ0^H6_F1RV%^_P!EOH%;8VV:TE"R&-FVLCX9=X)7#J6^/S7(H0J4:>:8&C6E
M3]^DZE.G52Z-P<E+E=[7M9Z*_0_6N%N-L0\/BZW#&>8S TZZ]CB8X;$8C"2D
MM7&-:%.=/G5F^1RYHV<DM>9*WX/^(-QX3T^_L5T]+X7,QNH'>Y>'R+AHDB8R
M*$?S8R(XVPIC;*GYCN!7XOB/@^EQ!C,)BGC'A/805*I%4XSYZ:DY+E?-'EDN
M:2N^>-FO=5FI?LWAQXPXOP^RC-LJCE$,T6-K/%4)SQ,Z/L<1*E"E)U(J%3VM
M-JG3ERP=&=XR3J/FBZ?&V^I:N/.M+.]OXUU";$UI:W-RB74TS;0KP1R8F=BP
M7#!B<@5]/++<%5GAY5,%1KUL,HQHSG1ISJ0M\*A)Q<HV>RC;78_,*?$6=X*A
MF%'#9SC,#@\PE.KBZ-'%XBC0K.5W.5:G"HH5+K1NHI-QT;9Z]IG@[Q-\(]=\
M)^-?%FCAM%AU"/[2+2>WNYK-[BWFC6.XB5L)=1HS2IABA>$*) V*^II8+%9-
MB,'CL90_<1FN91<9.+::LU?227O+I=6NF?F6(SC+.+,#FN2Y3C.7&2I/DYXS
MIQJ*$HN\9-7=.32A+3F497Y'$VOCM\2?#'C:+0+'PY)+>KITEU=W-_+:36BH
M;F*&-+2%+J-)6(V,TAVJF5CVE^2O1Q!FF$QRPU/"MS5)RE*;BX[I)12DD]+>
M]I;:USBX%X;S/(Y8^MF,8T'B%"$*49QF_<<FZDG!R@MTH*[E9RNH]?G2OFC]
M#"@#UO5]8U6X\ ?#R"XU74)XI]9\217$,U]<R1S0V-UH7V&.:-Y2)([?+>4K
M B/)V8S7KUZU6679;&56<E*I733DVFH2H\J:;U4?LWVZ6/E<'@\+2S[/YT\+
M2ISIX?!RA*-.$7&52&*]HXM13BYV7.U9RLN:YU/CH>&A=?%\Z;-K+:P;JU_M
M".]M["/3$QXKTOS/L$MO<O/)B7:!YD:?+DG!XKKQZPJGG7LG4]MS+G4E!0_W
MB%^1J3D]=KI:'EY(\Q]EPBL1##QPD:<O9.G*JZW^XUN7VL90C"/NWORRE[VV
MFI2^(UGJ \%^"[V)O%!T[_A&?"D4Z,4'A$.-.EVM&%NBQU;S?+!W6X&TM\^<
M QF4*BP.!J+V_LO88=-?\P]^1[>]_$OWC\S;AZMA_P"V,YH26"6(6,QTHM7^
MO6]M'>\+>PM>UJC=[>[:YO?$NX1O#VN06]SJ>L22W_@.QELKA4-CX6DC\,0W
M<$NEK]KF9EU,2R1LZ0VO[RVF1PV8S)OF<E]6KQC*=9N6$BXRMR4&J"DG3]Z3
M:JW:;48:QDG?1OAX<IN.88*=2E1PD84LSJ1J0;]IC4\;*G*-;]W!)X7EC)1<
MZON3A*+C:2CB^-O"]G:^!-*L+2[TJ?7/ 6!KUO97%O+?"#Q!)#+?&^CBC$B'
M3=<ECLAEG&RXWG:00<<=A(0R^C3A.G*OE_\ %C%Q<[56G+G25U[*JU3UOI*^
MFIV9+F=:IGF*KU:5>G@L]_W652$XTN;"1E&E[)M\K^LX:+KNR3O"VJM:EX[\
M1:;'H:^'!>ZKJFHW5MX%O5@O(432_#<5CX6M1+#I,K7LS227ANXGE,<%JOR,
M&WE06SQ^)I1PZPOM*E6I*.%E:22IT5##QNJ;<I-N?,G*T8+36YMD>7XEXYY@
MZ%#"8>C/,Z?-3DW7Q<JF.FXRKQ5."BJ/LY*"E.J]4URIM&Q\9=.U:%M2O?,\
M=MILFKPY35&C'A%8WBE\K^RQ'?R,3YHB$6^WC&TR=" #OG5*M'VD[XKV3J+2
MI;ZO:SM[.TWUMRWBM+[')P=B,)*.&H<N6QQ,,/+6C?Z]=2C?VUZ44M+\]JDO
M>Y=U=IGBBRFL]'^(^NSK'%I/BJ#P</#=X982FKE;FQOIA9*KEY##;PRF7Y1Y
M90JV&XI8J#IT<SQ$DHT<6L/["5U:I[T)OE5[OEBGS?RM6>H\LK0J8OAW TVY
M8K*98_ZY3Y97H>Y5I1]HVK+GG*/L]??3YHW6ID:IJVIWA^#,-WJ=]=0RVFG7
M<\5S>7$\4EU%XQUBUCN98Y9&5[A+51"LC L(P$!VC%8U:U6?]B1G5E).,)-.
M3:YEB:L5)IO=1]U/=+38Z\+A,-07&,Z.&I49QJ581E"G&#4'EV&FX1<4FHN;
M<W%:.?O6OJ7=$CU2YT_XC6?A!G_X3&;Q9;NJ65R++61X?ANM2:Y?2)XY8II!
M]N-L+B-'9?**LR<!A=!594LRIX)OZ[+$1LHRY:GL5*?-[-IJ3][EYTFURV=N
MICC98:EB.'JN;)+)X8&:;J0]IA_K<H45!8B+C."_=J?L9.*?/=*6MFO@.T\1
MZAJ'C/P_=2ZMI>IWNI6$VJ>*-+OHIY=$OK(ZME-8ECOEEN=!G:>87$T-R1&U
MO 6+[@"9?#$U*F-PTG4HU9S@ZE>$DW2E#VG\1J2;HRN^>2E[KC%N^P9[5R_#
M8?)L?2A0Q.&H4:L:."K4G&.(IU%0L\/%TW&&*IJ$?8PE33G&<U'ELVO"94\J
M22/>DGENZ;T.Y'V,5WHQ RC8R#@<&O :Y6U>_+U6VA]Q%WC%V<;I.ST:TV:Z
M-;,CH&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MK  )'3CMQQQZ4;>0?H)0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
,!0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
